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Abstract
Common variable immunodeficiency (CVID) is characterised by repeated infection 
associated with primary acquired hypogammaglobulinemia. CVID frequently has a complex 
aetiology but, in certain cases, it has a monogenic cause. Recently, variants within the gene 
encoding the transcription factor STAT3 were implicated in monogenic CVID. Here, we 
describe a patient presenting with symptoms synonymous with CVID, who displayed 
reduced levels of IgG and IgA, repeated viral infections and multiple additional co-
morbidities. Whole-exome sequencing revealed a de novo novel missense mutation in the 
coiled-coil domain of STAT3 (c.870A>T; p.K290N). Accordingly, the K290N variant of STAT3 
was generated, and a STAT3 responsive dual-luciferase reporter assay revealed that the 
variant strongly enhances STAT3 transcriptional activity both under basal and stimulated 
(with IL-6) conditions. Overall, these data complement earlier studies in which CVID-
associated STAT3 mutations are predicted to enhance transcriptional activity, suggesting 
that such patients may respond favourably to IL-6 receptor antagonists (e.g. tocilizumab).
Abbreviations:
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and activator of transcription; RSV, respiratory syncytial virus.
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1. Introduction
Common variable immunodeficiency (CVID) is the most common severe primary antibody 
deficiency disorder, characterised by acquired hypogammaglobulinemia and failure to mount 
an appropriate antibody response to infection or vaccination. CVID patients present with 
repeated bacterial infections and an increased incidence of certain autoimmune and 
neoplastic disorders [1]. The disease is thought to have a complex polygenic and 
multifactorial aetiology in most cases although causative mutations in single genes have 
been identified in a small proportion of patients [2]. Among the monogenic forms, mutations 
in PIK3CD and LRBA comprise approximately half of all reported cases, while mutations in a 
further 30 additional genes have also been proposed in the remainder [2]. STAT3 is one 
such gene and a recent study identified three potential gain-of-function mutations in STAT3 
among patients with CVID [3]. This is consistent with the emerging consensus that the 
majority of genes associated with monogenic CVID encode signalling proteins (including 
both receptors and downstream effectors) present in immune cells [2].  
STAT3 is a transcription factor whose activity is controlled by numerous cytokines, growth 
factors and hormones. It becomes phosphorylated on specific tyrosine residues in response 
to receptor activation and then dimerises before entering the nucleus to regulate the 
transcription of specific target genes. Interestingly, activating germline mutations in the 
STAT3 gene are relatively rare and the majority of such mutations are inactivating and 
implicated in conditions such as autosomal dominant hyper IgE syndrome [4, 5]. By contrast, 
where these have been described, the activating variants appear to predispose to various 
polyautoimmune diseases, including neonatal diabetes mellitus [6-8]. In the current report, 
we have employed whole exome sequencing of a patient with CVID to reveal a novel, 
causative, de novo mutation in the coiled-coil domain of STAT3. Functional studies show 
that this mutation strongly activates STAT3 under both basal conditions and following 
stimulation with IL-6, implying that this constitutive activation mediates the disease 
pathology.
Material and methods
2.1 Whole exome sequencing 
After obtaining written informed consent, genomic DNA was extracted from EDTA blood 
(QiAmp DNA Mini Kit; Qiagen, Hilden, Germany) or saliva samples (prepIT·L2P; DNA 
Genotek, Ottawa, Canada) from the affected individual and available family members. The 
project was approved by the East London and City Health Authority Research Ethics 
Committee and was conducted according to the Declaration of Helsinki Principles. 
The blood-derived DNA of the affected individual was subjected to whole exome 
sequencing. Exome capture and enrichment was performed using the NimbleGen SeqCap 
EZ Human Exome Library protocol (Roche Nimblegen, Madison, WI, USA). The subsequent 
DNA library was sequenced with 100 bp paired-end reads on the HiSeq 2000 platform 
(Illumina, San Diego, CA, USA). Resulting sequence data were aligned to the hg18 human 
reference genome using the Novoalign alignment tool (Novocraft Technologies Sdn Bhd, 
Petaling Jaya, Malaysia). Sequence variants were called with SAMtools and annotated via 
multiple passes through ANNOVAR [9].
2.2 Mutagenesis
The QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, 
USA) was employed to generate mutations within the human STAT3 gene (Source 
Bioscience, Nottingham, UK) using manufacturer’s guidelines. The primer pairs used to 
create each mutation were K290N; Fd: 
TCCCCTTTGTAGGAAACATTTTGCTGCAACTCCTCC Rv: 
TGGAGGAGTTGCAGCAAAATGTTTCCTACAAAGGGG Y640F; Fd: 
AGTCCGTGGAACCATTCACAAAGCAGCAGCTG Rv: 
AGCTGCTGCTTTGTGAATGGTTCCACGGACTG V637M Fd: 
AGACCCAGATCCAGTCCATGGAACCATACACAAAG, Rv: 
TGCTTTGTGTATGGTTCCATGGACTGGATCTGGGTC. The STAT3 insert was sequenced 
to confirm the success of mutagenesis (Source Bioscience). Finally STAT3 inserts were 
ligated between the AflII and EcoRV restriction sites within the polylinker of a 
pcDNA5/FRT/TO vector.
2.3 Cell culture
HEK293 cells were cultured in DMEM base media supplemented with 10% foetal bovine 
serum, 2mM L-glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin. Cells were 
cultured at 37oC and 5% CO2, and were sub-cultured upon reaching 80% confluence. 
2.4 STAT3 Reporter Assay
STAT3 transcriptional activity was investigated using the STAT3 responsive dual 
firefly/Renilla luciferase Cignal reporter system (Qiagen). Cells were seeded at a density of 1 
x 105 cells/well in a 24-well plate, and transfected into cells with 200ng of the Cignal reporter 
construct alongside 400ng of STAT3 constructs using Attractene transfection reagent 
according to the manufacturer’s guidelines (Qiagen). STAT3 activity was assessed 24h after 
transfection using a dual luciferase reporter system (Promega, Madison, WI, USA).
2.5 Western Blotting
Whole cell protein was extracted from HEK293 cells after lysis [10]. Protein was equalised, 
then denatured, prior to its loading onto pre-cast 4-12% Bis-Tris polyacrylamide gels 
(Thermo Fisher Scientific, Boston, MA, USA). Proteins were separated by electrophoresis, 
before their transfer onto PVDF membrane using a XCell II Blot module (Thermo Fisher 
Scientific). Immunoblotting was conducted using an iBind Flex Western device according to 
the manufacturer’s instructions (Thermo Fisher Scientific). Membranes were probed initially 
with antibodies raised against STAT3 (1:1000; Cell Signalling, Beverly, MA, USA; antibody 
registry: AB_331269) or β-actin (1:2000; Sigma-Aldrich, Poole, UK; antibody registry: 
AB_476744) and then subsequently with alkaline phosphatase conjugated secondary 
antibodies raised in the appropriate species. Bands were detected following exposure of 
membranes to CDP Star chemiluminescent reagent (Sigma-Aldrich) and then visualised 
using a cDigit blot scanner (LI-COR Biosciences, Lincoln, NE, USA).
Results
3.1 Patient description
The patient was diagnosed with common variable immunodeficiency (CVID) at age 14 on the 
basis of panhypogammaglobulinaemia and resistant idiopathic thrombocytopaenic purpura, 
for which splenectomy was performed (Supplementary table 1). She did not receive test 
vaccination. She had a history of haemolytic anaemia and idiopathic uveitis. Immunoglobulin 
replacement was started at CVID diagnosis. From early adulthood, the clinical course was 
complicated by CVID-related inflammatory arthritis, small and large intestinal inflammation, 
episodes of unexplained ascites, declining respiratory function, chronic hepatic dysfunction 
and chronic renal impairment. Inflammatory markers were consistently elevated. 
Furthermore, invasive cytomegalovirus (CMV) with gastric ulcer, typical CMV-related gastric 
inclusions and viraemia detected on PCR developed while taking mycophenolate and low 
dose prednisolone, prescribed for the inflammatory complications of CVID. After treatment 
with intravenous ganciclovir she required ongoing valganciclovir prophylaxis to prevent 
recurrent CMV viraemia, despite stopping mycophenolate, and maintaining corticosteroid 
dose at less than 10mg daily. 
More recently, at the age of 34 the patient was admitted to hospital with diarrhoea, vomiting, 
acute on chronic renal failure and was diagnosed with norovirus II. Thereafter the patient 
had several subsequent hospital admissions with episodes of acute on chronic renal failure, 
weight loss (8 Kg, 13% of body weight), anorexia, nausea, intermittent diarrhoea and 
difficulty maintaining an adequate trough IgG despite high doses of immunoglobulin. 
Parenteral feeding was commenced to manage the malnutrition that had developed in 
association with the chronic norovirus infection. During this period persistent rhinovirus was 
detected in respiratory secretions, and subsequent acute respiratory deterioration was 
associated with respiratory syncytial virus (RSV) acquisition. The respiratory viruses were 
successfully treated but despite a high blood level of ribavirin, norovirus was persistently 
detected in stool. The patient had previously had normal B cell (CD19+) numbers, mildly 
elevated T cells (CD3+) with inverted CD4+/8+ ratio and raised NK cells (CD16+/56+) in 
peripheral blood (Supplementary table 2). After contracting norovirus, B cell numbers fell, 
becoming undetectable in blood and bone marrow after a year. T-cell numbers fell more 
slowly to below the lower limit of normal and a large granular lymphocyte population 
(CD57+/CD8+) was evident (Supplementary table 2). The patient eventually succumbed, at 
the age of 38 years, to a combination of dialysis-dependent renal failure and infection. There 
was no family history of CVID or autoimmunity, although one sibling had received successful 
treatment for Hodgkin’s lymphoma. 
3.2 Identification of mutation
DNA was extracted from the blood or saliva of the patient, her siblings and parents. Variants 
were identified by whole exome sequencing and filtered for novelty by comparison to 
dbSNP137, 1000 genomes and an in-house database. From these analyses a heterozygous 
missense mutation in exon nine of STAT3 (c.870A>T; [p.K290N] (GenBank: NM_139276)) 
was identified. The mutation was a de novo event and not found in samples taken from 
either parent or two siblings, as confirmed by Sanger sequencing (Fig 1a). To our knowledge 
this mutation has not yet been reported in dbSNP, 1000 Genomes, and ExAC Browser. The 
mutation was signalled as damaging upon analysis by PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) with a score of 0.990 and was predicated as 
disease-causing by Mutation Taster (http://mutationtaster.org/). The K290N mutation resides 
within the coiled-coil domain of the STAT3 protein, a region which is highly conserved across 
multiple species (Fig 1b).
3.3 The K290N mutation increases STAT3 activity
To examine the effects of the K290N mutation on STAT3 activity, the mutant form was 
constructed and transfected into HEK293 cells in parallel with the wildtype. Western blotting 
analysis revealed a marked increase in STAT3 protein levels relative to cells transfected with 
empty vector, within 24h. Importantly, transfection with equal quantities of DNA encoding 
either K290N or wildtype STAT3 cDNA resulted in similar expression of STAT3 protein (Fig 
2a).
A STAT3-specific reporter assay was used to examine the transcriptional activity of the 
variant and revealed that introduction of the K290N substitution caused a ~16-fold increase 
in basal activity relative to the wildtype (Fig 2b). Treatment of cells with IL-6 for 24h 
promoted an increase in wildtype STAT3 activity (by ~19-fold) and led to a further 
enhancement of STAT3-K290N activity (totalling ~60-fold) above unstimulated wildtype cells, 
respectively (Fig 2c). Importantly, under these conditions, IL-6 also elicited a marked 
increase in the activity of the STAT3-K290N mutant beyond that observed in unstimulated 
cells expressing the mutant form. 
In these experiments, previously reported mutations which either enhance (Y640F) or inhibit 
(V637M) the activity of STAT3 were tested in parallel, to validate the assay system. These 
forms of STAT3 altered transcriptional activity in the expected directions under both IL-6 
stimulated and unstimulated conditions (Fig 2b & c). 
Discussion
We demonstrate that a novel de novo mutation in STAT3, discovered in a patient with CVID, 
results in a profound increase in transcriptional activity resulting from an amino acid 
substitution (asparagine for lysine) located at position 290 within the coiled-coil domain of 
the protein. As such, the present work supports earlier evidence in which activating 
mutations in STAT3 were also found in three other patients with CVID [3]. These vary in that 
they occur at different residues within the protein, but it seems significant that three of the 
variants (including that identified here) lie within the coiled-coil domain. Furthermore, each 
promotes the acquisition of gain-of-function properties by enhancing the transcriptional 
activity of STAT3 [3]. Taken together, the data suggest very strongly that mutations with the 
coiled-coil domain of STAT3 can promote the transcriptional activity of STAT3 and that this 
altered phenotype is pathogenic for CVID. 
The clinical phenotype of the patient was typical for CVID. The patient presented with 
reduced IgG and IgA levels, however IgM was within the normal range, these observations 
are similar to those described in CVID patients with other mutations in STAT3 [3]. In 
addition, in the current study changes in the immune cell profile were noted, including an 
elevation in CD3+ T-cells and a reduction in the CD4+/CD8+ cell ratio. Similar profiles have 
been observed in previously published CVID cases [11]. The patient experienced repeated 
infections as well as liver and gastrointestinal disease, however malignancy, although 
commonly reported in CVID patients [1], did not develop. These data highlight the variability 
of CVID even when caused by mutations within the same gene. In the case of STAT3, the 
mode of activation probably differs in subtle ways for each mutation leading to the variable 
patient phenotypes. Such considerations should be included in the planning of the clinical 
management for a patient with the disease.
The coiled-coil domain plays an important role in regulating the nuclear import of STAT3, 
and it is known that modification of residues within this domain can disrupt or abrogate 
nuclear translocation. This process is thought to be regulated by at least two distinct regions 
within the coiled-coil domain and, in particular, residues located between amino acids 150-
163 [12] and at 214-215 have been implicated [13]. Clearly, the mutation we have identified 
(K290N) lies outside these regions and might not, then, be immediately implicated in altered 
nuclear localisation. However, changes in the folding of STAT3 arising from the loss of a 
positively charged lysine residue might influence its nuclear retention and, it is also possible 
that the mutation leads to the generation of a novel nuclear localisation sequence per se. In 
this context, the use of predictive algorithms (NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/) reveals that the K290N mutation generates a 
novel motif (QNVSYK) at which N-glycosylation is predicted to occur (on the substituted 
asparagine residue). Such a change in glycosylation status could influence the subcellular 
localisation of the protein, including facilitation of nuclear entry [14]. In the present work, we 
have not proven directly that the K290N mutant is preferentially retained in the nucleus 
although this would be consistent with the activating phenotype and with a recent report 
documenting sustained nuclear retention as a mechanism for STAT3 activation associated 
with another activating variant [15].
In support of the present data, others have reported that increased tyrosine phosphorylation 
of STAT3 (and, therefore, enhanced nuclear import and activation of transcriptional activity) 
is detectable in the memory B-cell population of patients with CVID [16]. This was associated 
with elevated apoptotic rates in these cells, both under control conditions and upon 
stimulation with relevant cytokines, and could provide one mechanism by which B-cells are 
depleted in the disease. Given that we find a greatly enhanced response to IL-6 in the 
K290N mutant, IL-6 receptor antagonists, such as tocilizumab, may provide a relatively non-
toxic therapeutic option for managing the autoimmunity. Indeed, this approach has been 
used successfully in other disease contexts, such as rheumatoid arthritis, where activation of 
STAT3 has been implicated as causative [17, 18].
Finally, it is important to emphasise that, while constitutive activation of STAT3 can lead to 
the development of CVID, it is also clear that alternative pathological phenotypes can 
develop from such mutations. For example, certain activating germline mutations in STAT3 
have been implicated in the early onset of poly-autoimmune phenotypes rather than 
hypogammaglobulinaemia [6]. Furthermore, somatic mutations leading to STAT3 activation 
have also been described in patients with rare forms of cancer [19, 20]. It remains to be 
established why different gain-of-function mutations in STAT3 cause variable disease 
phenotypes but this may be related to differences in the degree of activation associated with 
each mutation and their propensity to alter protein-protein interactions within the signalling 
cascade. 
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Figure legends
Figure 1. A de novo mutation identified in the coiled-coil domain of STAT3 in a CVID patient. 
(a) Whole exome sequencing identified a mutation (K290N) within STAT3 from a patient with 
CVID, this was absent from parents and siblings of the affected individual. (b) The mutation 
was located within the coiled-coil domain of STAT3, and was in a highly conserved region of 
the protein. Other reported STAT3 mutations associated with CVID are also indicated.    
Figure 2. Transfection of K290N-STAT3 into cells increased STAT3 activity. (a) HEK293 
cells were transfected with equal amounts of an empty vector, wildtype STAT3 or K290N 
and expression of STAT3 was studied by Western blotting. Results are representative of two 
separate experiments. (b) Cells were alternatively transfected with wildtype, K290N and 
mutations which are known to activate (Y640F) and inactivate (V637M) STAT3. These cells 
were either grown in the presence or absence of 20ng/ml IL-6, and transcriptional activity 
was determined using a dual-luciferase reporter assay (n = 3-6). ***p<0.001.
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Abstract
Common variable immunodeficiency (CVID) is characterised by repeated infection 
associated with primary acquired hypogammaglobulinemia. CVID frequently has a complex 
aetiology but, in certain cases, it has a monogenic cause. Recently, variants within the gene 
encoding the transcription factor STAT3 were implicated in monogenic CVID. Here, we 
describe a patient presenting with symptoms synonymous with CVID, who displayed 
reduced levels of IgG and IgA, repeated viral infections and multiple additional co-
morbidities. Whole-exome sequencing revealed a de novo novel missense mutation in the 
coiled-coil domain of STAT3 (c.870A>T; p.K290N). Accordingly, the K290N variant of STAT3 
was generated, and a STAT3 responsive dual-luciferase reporter assay revealed that the 
variant strongly enhances STAT3 transcriptional activity both under basal and stimulated 
(with IL-6) conditions. Overall, these data complement earlier studies in which CVID-
associated STAT3 mutations are predicted to enhance transcriptional activity, suggesting 
that such patients may respond favourably to IL-6 receptor antagonists (e.g. tocilizumab).
Abbreviations:
CMV, cytomegalovirus; CVID, Common variable immunodeficiency; STAT, signal transducer 
and activator of transcription; RSV, respiratory syncytial virus.
Keywords:
Common variable immunodeficiency; CVID; hypogammaglobulinemia; STAT3; whole exome 
sequencing.
1. Introduction
Common variable immunodeficiency (CVID) is the most common severe primary antibody 
deficiency disorder, characterised by acquired hypogammaglobulinemia and failure to mount 
an appropriate antibody response to infection or vaccination. CVID patients present with 
repeated bacterial infections and an increased incidence of certain autoimmune and 
neoplastic disorders [1]. The disease is thought to have a complex polygenic and 
multifactorial aetiology in most cases although causative mutations in single genes have 
been identified in a small proportion of patients [2]. Among the monogenic forms, mutations 
in PIK3CD and LRBA comprise approximately half of all reported cases, while mutations in a 
further 30 additional genes have also been proposed in the remainder [2]. STAT3 is one 
such gene and a recent study identified three potential gain-of-function mutations in STAT3 
among patients with CVID [3]. This is consistent with the emerging consensus that the 
majority of genes associated with monogenic CVID encode signalling proteins (including 
both receptors and downstream effectors) present in immune cells [2].  
STAT3 is a transcription factor whose activity is controlled by numerous cytokines, growth 
factors and hormones. It becomes phosphorylated on specific tyrosine residues in response 
to receptor activation and then dimerises before entering the nucleus to regulate the 
transcription of specific target genes. Interestingly, activating germline mutations in the 
STAT3 gene are relatively rare and the majority of such mutations are inactivating and 
implicated in conditions such as autosomal dominant hyper IgE syndrome [4, 5]. By contrast, 
where these have been described, the activating variants appear to predispose to various 
polyautoimmune diseases, including neonatal diabetes mellitus [6-8]. In the current report, 
we have employed whole exome sequencing of a patient with CVID to reveal a novel, 
causative, de novo mutation in the coiled-coil domain of STAT3. Functional studies show 
that this mutation strongly activates STAT3 under both basal conditions and following 
stimulation with IL-6, implying that this constitutive activation mediates the disease 
pathology.
Material and methods
2.1 Whole exome sequencing 
After obtaining written informed consent, genomic DNA was extracted from EDTA blood 
(QiAmp DNA Mini Kit; Qiagen, Hilden, Germany) or saliva samples (prepIT·L2P; DNA 
Genotek, Ottawa, Canada) from the affected individual and available family members. The 
project was approved by the East London and City Health Authority Research Ethics 
Committee and was conducted according to the Declaration of Helsinki Principles. 
The blood-derived DNA of the affected individual was subjected to whole exome 
sequencing. Exome capture and enrichment was performed using the NimbleGen SeqCap 
EZ Human Exome Library protocol (Roche Nimblegen, Madison, WI, USA). The subsequent 
DNA library was sequenced with 100 bp paired-end reads on the HiSeq 2000 platform 
(Illumina, San Diego, CA, USA). Resulting sequence data were aligned to the hg18 human 
reference genome using the Novoalign alignment tool (Novocraft Technologies Sdn Bhd, 
Petaling Jaya, Malaysia). Sequence variants were called with SAMtools and annotated via 
multiple passes through ANNOVAR [9].
2.2 Mutagenesis
The QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, 
USA) was employed to generate mutations within the human STAT3 gene (Source 
Bioscience, Nottingham, UK) using manufacturer’s guidelines. The primer pairs used to 
create each mutation were K290N; Fd: 
TCCCCTTTGTAGGAAACATTTTGCTGCAACTCCTCC Rv: 
TGGAGGAGTTGCAGCAAAATGTTTCCTACAAAGGGG Y640F; Fd: 
AGTCCGTGGAACCATTCACAAAGCAGCAGCTG Rv: 
AGCTGCTGCTTTGTGAATGGTTCCACGGACTG V637M Fd: 
AGACCCAGATCCAGTCCATGGAACCATACACAAAG, Rv: 
TGCTTTGTGTATGGTTCCATGGACTGGATCTGGGTC. The STAT3 insert was sequenced 
to confirm the success of mutagenesis (Source Bioscience). Finally STAT3 inserts were 
ligated between the AflII and EcoRV restriction sites within the polylinker of a 
pcDNA5/FRT/TO vector.
2.3 Cell culture
HEK293 cells were cultured in DMEM base media supplemented with 10% foetal bovine 
serum, 2mM L-glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin. Cells were 
cultured at 37oC and 5% CO2, and were sub-cultured upon reaching 80% confluence. 
2.4 STAT3 Reporter Assay
STAT3 transcriptional activity was investigated using the STAT3 responsive dual 
firefly/Renilla luciferase Cignal reporter system (Qiagen). Cells were seeded at a density of 1 
x 105 cells/well in a 24-well plate, and transfected into cells with 200ng of the Cignal reporter 
construct alongside 400ng of STAT3 constructs using Attractene transfection reagent 
according to the manufacturer’s guidelines (Qiagen). STAT3 activity was assessed 24h after 
transfection using a dual luciferase reporter system (Promega, Madison, WI, USA).
2.5 Western Blotting
Whole cell protein was extracted from HEK293 cells after lysis [10]. Protein was equalised, 
then denatured, prior to its loading onto pre-cast 4-12% Bis-Tris polyacrylamide gels 
(Thermo Fisher Scientific, Boston, MA, USA). Proteins were separated by electrophoresis, 
before their transfer onto PVDF membrane using a XCell II Blot module (Thermo Fisher 
Scientific). Immunoblotting was conducted using an iBind Flex Western device according to 
the manufacturer’s instructions (Thermo Fisher Scientific). Membranes were probed initially 
with antibodies raised against STAT3 (1:1000; Cell Signalling, Beverly, MA, USA; antibody 
registry: AB_331269) or β-actin (1:2000; Sigma-Aldrich, Poole, UK; antibody registry: 
AB_476744) and then subsequently with alkaline phosphatase conjugated secondary 
antibodies raised in the appropriate species. Bands were detected following exposure of 
membranes to CDP Star chemiluminescent reagent (Sigma-Aldrich) and then visualised 
using a cDigit blot scanner (LI-COR Biosciences, Lincoln, NE, USA).
Results
3.1 Patient description
The patient was diagnosed with common variable immunodeficiency (CVID) at age 14 on the 
basis of panhypogammaglobulinaemia and resistant idiopathic thrombocytopaenic purpura, 
for which splenectomy was performed (Supplementary table 1). She had a history of 
haemolytic anaemia and idiopathic uveitis. Immunoglobulin replacement was started at CVID 
diagnosis. From early adulthood, the clinical course was complicated by CVID-related 
inflammatory arthritis, small and large intestinal inflammation, episodes of unexplained 
ascites, declining respiratory function, chronic hepatic dysfunction and chronic renal 
impairment. Inflammatory markers were consistently elevated. Furthermore, invasive 
cytomegalovirus (CMV) with gastric ulcer, typical CMV-related gastric inclusions and 
viraemia detected on PCR developed while taking mycophenolate and low dose 
prednisolone, prescribed for the inflammatory complications of CVID. After treatment with 
intravenous ganciclovir she required ongoing valganciclovir prophylaxis to prevent recurrent 
CMV viraemia, despite stopping mycophenolate, and maintaining corticosteroid dose at less 
than 10mg daily. 
More recently, at the age of 34 the patient was admitted to hospital with diarrhoea, vomiting, 
acute on chronic renal failure and was diagnosed with norovirus II. Thereafter the patient 
had several subsequent hospital admissions with episodes of acute on chronic renal failure, 
weight loss (8 Kg, 13% of body weight), anorexia, nausea, intermittent diarrhoea and 
difficulty maintaining an adequate trough IgG despite high doses of immunoglobulin. 
Parenteral feeding was commenced to manage the malnutrition that had developed in 
association with the chronic norovirus infection. During this period persistent rhinovirus was 
detected in respiratory secretions, and subsequent acute respiratory deterioration was 
associated with respiratory syncytial virus (RSV) acquisition. The respiratory viruses were 
successfully treated but despite a high blood level of ribavirin, norovirus was persistently 
detected in stool. The patient had previously had normal B cell (CD19+) numbers, mildly 
elevated T cells (CD3+) with inverted CD4+/8+ ratio and raised NK cells (CD16+/56+) in 
peripheral blood (Supplementary table 2). After contracting norovirus, B cell numbers fell, 
becoming undetectable in blood and bone marrow after a year. T-cell numbers fell more 
slowly to below the lower limit of normal and a large granular lymphocyte population 
(CD57+/CD8+) was evident (Supplementary table 2). The patient eventually succumbed, at 
the age of 38 years, to a combination of dialysis-dependent renal failure and infection. There 
was no family history of CVID or autoimmunity, although one sibling had received successful 
treatment for Hodgkin’s lymphoma. 
3.2 Identification of mutation
DNA was extracted from the blood or saliva of the patient, her siblings and parents. Variants 
were identified by whole exome sequencing and filtered for novelty by comparison to 
dbSNP137, 1000 genomes and an in-house database. From these analyses a heterozygous 
missense mutation in exon nine of STAT3 (c.870A>T; [p.K290N] (GenBank: NM_139276)) 
was identified. The mutation was a de novo event and not found in samples taken from 
either parent or two siblings, as confirmed by Sanger sequencing (Fig 1a). To our knowledge 
this mutation has not yet been reported in dbSNP, 1000 Genomes, and ExAC Browser. The 
mutation was signalled as damaging upon analysis by PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) with a score of 0.990 and was predicated as 
disease-causing by Mutation Taster (http://mutationtaster.org/). The K290N mutation resides 
within the coiled-coil domain of the STAT3 protein, a region which is highly conserved across 
multiple species (Fig 1b).
3.3 The K290N mutation increases STAT3 activity
To examine the effects of the K290N mutation on STAT3 activity, the mutant form was 
constructed and transfected into HEK293 cells in parallel with the wildtype. Western blotting 
analysis revealed a marked increase in STAT3 protein levels relative to cells transfected with 
empty vector, within 24h. Importantly, transfection with equal quantities of DNA encoding 
either K290N or wildtype STAT3 cDNA resulted in similar expression of STAT3 protein (Fig 
2a).
A STAT3-specific reporter assay was used to examine the transcriptional activity of the 
variant and revealed that introduction of the K290N substitution caused a ~16-fold increase 
in basal activity relative to the wildtype (Fig 2b). Treatment of cells with IL-6 for 24h 
promoted an increase in wildtype STAT3 activity (by ~19-fold) and led to a further 
enhancement of STAT3-K290N activity (totalling ~60-fold) above unstimulated wildtype cells, 
respectively (Fig 2c). Importantly, under these conditions, IL-6 also elicited a marked 
increase in the activity of the STAT3-K290N mutant beyond that observed in unstimulated 
cells expressing the mutant form. 
In these experiments, previously reported mutations which either enhance (Y640F) or inhibit 
(V637M) the activity of STAT3 were tested in parallel, to validate the assay system. These 
forms of STAT3 altered transcriptional activity in the expected directions under both IL-6 
stimulated and unstimulated conditions (Fig 2b & c). 
Discussion
We demonstrate that a novel de novo mutation in STAT3, discovered in a patient with CVID, 
results in a profound increase in transcriptional activity resulting from an amino acid 
substitution (asparagine for lysine) located at position 290 within the coiled-coil domain of 
the protein. As such, the present work supports earlier evidence in which activating 
mutations in STAT3 were also found in three other patients with CVID [3]. These vary in that 
they occur at different residues within the protein, but it seems significant that three of the 
variants (including that identified here) lie within the coiled-coil domain. Furthermore, each 
promotes the acquisition of gain-of-function properties by enhancing the transcriptional 
activity of STAT3 [3]. Taken together, the data suggest very strongly that mutations with the 
coiled-coil domain of STAT3 can promote the transcriptional activity of STAT3 and that this 
altered phenotype is pathogenic for CVID. 
The clinical phenotype of the patient was typical for CVID. The patient presented with 
reduced IgG and IgA levels, however IgM was within the normal range, these observations 
are similar to those described in CVID patients with other mutations in STAT3 [3]. In 
addition, in the current study changes in the immune cell profile were noted, including an 
elevation in CD3+ T-cells and a reduction in the CD4+/CD8+ cell ratio. Similar profiles have 
been observed in previously published CVID cases [11]. The patient experienced repeated 
infections as well as liver and gastrointestinal disease, however lung disease and 
malignancy, although commonly reported in CVID patients [1], did not develop. These data 
highlight the variability of CVID even when caused by mutations within the same gene. In the 
case of STAT3, the mode of activation probably differs in subtle ways for each mutation 
leading to the variable patient phenotypes. Such considerations should be included in the 
planning of the clinical management for a patient with the disease.
The coiled-coil domain plays an important role in regulating the nuclear import of STAT3, 
and it is known that modification of residues within this domain can disrupt or abrogate 
nuclear translocation. This process is thought to be regulated by at least two distinct regions 
within the coiled-coil domain and, in particular, residues located between amino acids 150-
163 [12] and at 214-215 have been implicated [13]. Clearly, the mutation we have identified 
(K290N) lies outside these regions and might not, then, be immediately implicated in altered 
nuclear localisation. However, changes in the folding of STAT3 arising from the loss of a 
positively charged lysine residue might influence its nuclear retention and, it is also possible 
that the mutation leads to the generation of a novel nuclear localisation sequence per se. In 
this context, the use of predictive algorithms (NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/) reveals that the K290N mutation generates a 
novel motif (QNVSYK) at which N-glycosylation is predicted to occur (on the substituted 
asparagine residue). Such a change in glycosylation status could influence the subcellular 
localisation of the protein, including facilitation of nuclear entry [14]. In the present work, we 
have not proven directly that the K290N mutant is preferentially retained in the nucleus 
although this would be consistent with the activating phenotype and with a recent report 
documenting sustained nuclear retention as a mechanism for STAT3 activation associated 
with another activating variant [15].
In support of the present data, others have reported that increased tyrosine phosphorylation 
of STAT3 (and, therefore, enhanced nuclear import and activation of transcriptional activity) 
is detectable in the memory B-cell population of patients with CVID [16]. This was associated 
with elevated apoptotic rates in these cells, both under control conditions and upon 
stimulation with relevant cytokines, and could provide one mechanism by which B-cells are 
depleted in the disease. Given that we find a greatly enhanced response to IL-6 in the 
K290N mutant, IL-6 receptor antagonists, such as tocilizumab, may provide a relatively non-
toxic therapeutic option for managing the autoimmunity. Indeed, this approach has been 
used successfully in other disease contexts, such as rheumatoid arthritis, where activation of 
STAT3 has been implicated as causative [17, 18].
Finally, it is important to emphasise that, while constitutive activation of STAT3 can lead to 
the development of CVID, it is also clear that alternative pathological phenotypes can 
develop from such mutations. For example, certain activating germline mutations in STAT3 
have been implicated in the early onset of poly-autoimmune phenotypes rather than 
hypogammaglobulinaemia [6]. Furthermore, somatic mutations leading to STAT3 activation 
have also been described in patients with rare forms of cancer [19, 20]. It remains to be 
established why different gain-of-function mutations in STAT3 cause variable disease 
phenotypes but this may be related to differences in the degree of activation associated with 
each mutation and their propensity to alter protein-protein interactions within the signalling 
cascade. 
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Figure legends
Figure 1. A de novo mutation identified in the coiled-coil domain of STAT3 in a CVID patient. 
(a) Whole exome sequencing identified a mutation (K290N) within STAT3 from a patient with 
CVID, this was absent from parents and siblings of the affected individual. (b) The mutation 
was located within the coiled-coil domain of STAT3, and was in a highly conserved region of 
the protein. Other reported STAT3 mutations associated with CVID are also indicated.    
Figure 2. Transfection of K290N-STAT3 into cells increased STAT3 activity. (a) HEK293 
cells were transfected with equal amounts of an empty vector, wildtype STAT3 or K290N 
and expression of STAT3 was studied by Western blotting. Results are representative of two 
separate experiments. (b) Cells were alternatively transfected with wildtype, K290N and 
mutations which are known to activate (Y640F) and inactivate (V637M) STAT3. These cells 
were either grown in the presence or absence of 20ng/ml IL-6, and transcriptional activity 
was determined using a dual-luciferase reporter assay (n = 3-6). ***p<0.001.
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Supplementary Table 1: Laboratory parameters
Aged 14-20y Aged 35-38y
Blood count
Haemoglobin
(NR 11.5-16.5g/dL) 
Neutrophils
(NR 2-7.5x109/L) 
Lymphocytes
(NR 1.5-4x109/L)
CD3+ cells
(NR 918-2023x106/L)
CD4+/8+ cell ratio
(NR 0.9-1.9) 
CD19+ cells*
(NR 42-461x106/L)
CD56+ cells
(NR 41-339x106/L) 
Platelets
(NR 150-400x109/L)
8.2-13.0g/dL 
2.3-9.4x109/L 
2.0-6.7x109/L
3601-4526x106/L ()
0.55 ()
574-552x106/L ()
96x106/L
9-12x109/L ()
9.4-10.5g/dL ()
7.9-11.8x109/L ()
2.0-9.5x109/L
1944-8927x106/L ()
0.47-0.8 ()
<1-48x106/L ()
77-278x106/L
257-345x109/L
C-reactive protein
(NR<5)
30-64mg/L () 44-116mg/L ()
Creatinine
(NR<90)
142-168 µmol/L() 231-306** µmol/L()
Liver function
Aspartate aminotransferase 
(AST) (NR 13-35U/L)
Alanine aminotransferase 
(ALT) (NR 7-35 U/L)
Alkaline phosphatase (AP) 
(NR 30-130 U/L)
Gamma-glutamyl transferase 
(GGT) (NR 5-39 U/L)
16-23 U/L
11-29 U/L 
111-183 U/L 
96-158U/L ()
14–18 U/L
7-8 U/L
75-505 U/L
164-464 U/L ()
Immunoglobulins
IgG (NR 7-16g/L)
IgA (NR 0.8-4g/L)
IgM (NR 0.4-2g/L)
4.5g/L()
0.3-0.4g/L ()
0.8-0.9g/L 
10-13g/L***
0.05-0.11g/L ()
0.45- 0.63g/L 
Vaccine Responses N/A N/A
*switched memory B cells not tested, **dialysis-dependent from age 3, ***post-
immunoglobulin replacement. NR=normal range 
Supplementary Table 2. Histological findings 
Tissue Age at 
sampling
Report
Spleen 13 years Lymphocytosis of red pulp
Focal aggregates of foamy macrophages
Liver 28 years Prominent lymphoid aggregates centred around the bile ducts 
with moderate fibrous expansion, focal bridging necrosis and 
some ductopenia. Mild interface hepatitis and sinusoidal 
dilatation in hepatic lobules, with foci of hepatocyte dropout and 
associated chronic inflammation. 
Duodenum 34 years Almost devoid of surface glandular epithelium. Intact villi are of 
normal architecture with no villous blunting or increase in 
intraepithelial lymphocytes. No nodular lymphoid hyperplasia, 
granuloma, active inflammation or ulceration. No giardia, 
cryptosporidia or CMV. Absent CD138+ plasma cells within 
lamina propria. 
Termimal 
ileum
34 years Mild villous distortion, oedema and patchy neutrophilic infiltrate 
within the lamina propria with focal cryptitis. Absent plasma 
cells. No granuloma formation. No luminal organisms or CMV-
like viral inclusions.
Colon 35 years Preserved crypt architecture showing paucicellular lamina 
propria with no plasma cells. No active inflammation or 
granulomata. 
Bone 
Marrow
35 years Hypocellular. Three haemopoietic series identified with 
maturation. Few Megakaryocytes and occasional T 
lymphocytes present. No dysplastic features, fibrosis or 
granulomas. 
Flow cytometry: Reversed CD4:CD8 ratio. High percentage of 
LGLs (large granular lymphocytes). Fifteen percent of all white 
blood cells are CD14+ CD11B+ monocytes. Absent B-cells. No 
obvious infiltrate.
Peripheral 
blood
35 years Flow cytometry: Reversed CD4:CD8 ratio. Increased CD57+ 
CD8+ population. Absent B-cells. 
